公开(公告)号：CA2858316A1

公开(公告)日：2013-06-13

申请号：CA2858316

申请日：2012-12-03

Applicant: BASF SE

Inventor： HAFNER ANDREAS ,  HINTERMANN TOBIAS ,  BLATTER FRITZ ,  RODEL EVA

IPC: C07D403/10 ,  A61K31/506 ,  A61P31/10

Abstract: A novel solid form of Voriconazole comprises the active ingredient (2R,3S)-2-(2,4- difluorophenyl)- 3-(5-fluoropyrimidin- 4-yl)-1 -(1H-1,2,4-triazol-1 -yl)butan-2-ol and fumaric acid. The solid composition comprising the two components shows improved properties such as water solubility, crystallization behavior and stability.

公开(公告)号：CA2832343A1

公开(公告)日：2012-10-26

申请号：CA2832343

申请日：2012-04-16

Applicant: BASF SE

Inventor： HAFNER ANDREAS ,  BLATTER FRITZ ,  SZELAGIEWICZ MARTIN ,  SIEBENHAAR BERND

IPC: C07D239/42 ,  A61K31/505 ,  A61P9/00

Abstract: A novel solid form of Rosuvastatin comprises as the active ingredient a salt of bis[(E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)-amino]pyrimidin-5-yl]-(3R,5S)-3,5-dihydroxyhept-6-enoic acid] and vanillin or vanillin derivatives. The crystal comprising the two components, and minor amounts of water, shows improved properties such as crystallization behavior stability and decreased hydroscopic behavior.

公开(公告)号：CA2917183C

公开(公告)日：2019-01-29

申请号：CA2917183

申请日：2014-07-22

Applicant: BASF SE

Inventor： HAFNER ANDREAS ,  BLATTER FRITZ ,  SZELAGIEWICZ MARTIN ,  SIEBENHAAR BERND ,  CHIODO TIZIANA ,  HINTERMANN TOBIAS ,  SALVADOR BEATE ,  VOSSEN MARCUS

IPC: C07D417/12 ,  A61K31/191 ,  A61K31/428 ,  A61K31/455 ,  A61K31/506 ,  C07C55/12 ,  C07D213/80 ,  C07D275/06

Abstract: The present invention primarily relates to molecular crystalline substances, preferably salts of Dasatinib in crystalline form, comprising a compound of formula 1, preferably a cation of a compound of formula 1, and a second compound selected from the group consisting of glutaric acid, nicotinic acid and saccharin, preferably an anion thereof. The invention is further related to pharmaceutical compositions comprising such a substance. Furthermore, the invention relates to processes for preparing said substances. The invention also relates to several aspects of using said substances or pharmaceutical compositions to treat a disease.

公开(公告)号：AU2013333953B2

公开(公告)日：2017-08-31

申请号：AU2013333953

申请日：2013-10-16

Applicant: BASF SE

Inventor： CHIODO TIZIANA ,  HAFNER ANDREAS ,  HINTERMANN TOBIAS ,  SALVADOR BEATE ,  SZELAGIEWICZ MARTIN ,  BLATTER FRITZ ,  RODEL EVA ,  VOSSEN MARCUS

IPC: C07D401/14 ,  A61K31/506 ,  A61P35/02

Abstract: The present invention relates to crystalline materials comprising nilotinib and a carboxylic acid, carboxylic acid ester, carboxylic acid amide or sulfonic acid as a co-crystal former, and to pharmaceutical compositions comprising said materials. The invention also relates to processes for preparing said crystalline materials and to methods of using said crystalline materials to treat a disease condition in which tyrosine kinase inhibition is beneficial.

公开(公告)号：AU2014295143A1

公开(公告)日：2016-02-11

申请号：AU2014295143

申请日：2014-07-22

Applicant: BASF SE

Inventor： HAFNER ANDREAS ,  BLATTER FRITZ ,  SZELAGIEWICZ MARTIN ,  SIEBENHAAR BERND ,  CHIODO TIZIANA ,  HINTERMANN TOBIAS ,  SALVADOR BEATE ,  VOSSEN MARCUS

IPC: C07D417/12

Abstract: The present invention primarily relates to salts of Dasatinib, wherein the salts are in amorphous form. The salts described herein preferably comprise a cation of a compound of formula 1 and an anion of a second compound selected from the group consisting of glutaric acid, nicotinic acid and saccharin. The invention is further related to pharmaceutical compositions comprising such a salt. Furthermore, the invention relates to processes for preparing said salts. The invention also relates to several aspects of using said salt or pharmaceutical composition to treat a disease.

公开(公告)号：AU2013276138A1

公开(公告)日：2015-01-22

申请号：AU2013276138

申请日：2013-06-13

Applicant: BASF SE

Inventor： CHIODO TIZIANA ,  HAFNER ANDREAS ,  HINTERMANN TOBIAS ,  SALVADOR BEATE ,  SZELAGIEWICZ MARTIN ,  BLATTER FRITZ ,  SIEBENHAAR BERND ,  VOSSEN MARCUS

IPC: C07D417/12 ,  A61K31/506 ,  A61P35/00

Abstract: The present invention refers to a multicomponent crystalline system (co-crystal) comprising a compound of formula 1 (INN: Dasatinib) and a second compound selected from methyl-4-hydroxybenzoate, or nicotinamide, or ethyl gallate, or methyl gallate, or propyl gallate, or ethyl maltol or vanillin, or men- thol, or (1R,2S,5R)-(-)-menthol,as well as to a process for obtaining the same.

公开(公告)号：DE112016000315A5

公开(公告)日：2017-10-05

申请号：DE112016000315

申请日：2016-01-12

Applicant: BASF SE

Inventor： BUJARD PATRICE ,  DABBOUS RAPHAËL ,  STRUB ANDREAS ,  HAFNER ANDREAS

IPC: G10K11/165 ,  G10K11/168

公开(公告)号：AU2015370497A1

公开(公告)日：2017-07-13

申请号：AU2015370497

申请日：2015-12-18

Applicant: BASF SE

Inventor： STALDER MARTIN ,  GALLINET BENJAMIN ,  LUETOLF FABIAN ,  BASSET GUILLAUME ,  FERRINI ROLANDO ,  BUJARD PATRICE ,  VON MUEHLENEN ADRIAN ,  HAFNER ANDREAS

IPC: G02B5/18 ,  G02B5/20

Abstract: A translucent or transparent film or sheet comprises a substrate (1) covered with a layer of a dielectric high refractive index material (4) containing a thin metallic layer (3) embedded in material, and a further layer (5) of translucent or transparent material covering layer of a dielectric high refractive index material (4), the embedded metal layer (3) is periodically interrupted with a periodicity of 50 to 800nm such that metal covers at least 70% of the substrate area. Also provided a window, glas façade element or solar panel comprising the film or sheet, a method for manufacturing the film or sheet, and a method for reducing the transmission of solar IR radiation using the the film or sheet.

公开(公告)号：AU2013276138B2

公开(公告)日：2017-02-23

申请号：AU2013276138

申请日：2013-06-13

Applicant: BASF SE

Inventor： CHIODO TIZIANA ,  HAFNER ANDREAS ,  HINTERMANN TOBIAS ,  SALVADOR BEATE ,  SZELAGIEWICZ MARTIN ,  BLATTER FRITZ ,  SIEBENHAAR BERND ,  VOSSEN MARCUS

IPC: C07D417/12 ,  A61K31/506 ,  A61P35/00

Abstract: The present invention refers to a multicomponent crystalline system (co-crystal) comprising a compound of formula 1 (INN: Dasatinib) and a second compound selected from methyl-4-hydroxybenzoate, or nicotinamide, or ethyl gallate, or methyl gallate, or propyl gallate, or ethyl maltol or vanillin, or men- thol, or (1R,2S,5R)-(-)-menthol,as well as to a process for obtaining the same.

公开(公告)号：ES2598168T3

公开(公告)日：2017-01-25

申请号：ES13750525

申请日：2013-08-05

Applicant: BASF SE

Inventor： HAFNER ANDREAS ,  BLATTER FRITZ ,  RÖDEL EVA ,  SZELAGIEWICZ MARTIN ,  CHIODO TIZIANA ,  HINTERMANN TOBIAS ,  SALVADOR BEATE ,  VOSSEN MARCUS

IPC: C07D213/81 ,  A61K31/4196 ,  A61P7/00 ,  C07D249/08

Abstract: Cocristal que comprende un compuesto de fórmula 1 (ácido 4-[3,5-bis(2-hidroxifenil)-1H-1,2,4-triazol-1-il]benzoico;**Fórmula** INN: deferasirox) y un compuesto de fórmula 2 (isonicotinamida; piridina-4-carboxamida)**Fórmula**